Galactomannan antigen detection using bronchial wash and bronchoalveolar lavage in patients with hematologic malignancies
Open Access
- 14 November 2015
- journal article
- research article
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 14 (1) , 50
Abstract
The diagnosis of invasive pulmonary aspergillosis is challenging. It is unclear whether galactomannan (GM) results from bronchial wash (BW) and bronchoalveolar lavage (BAL) samples differ in a clinically meaningful way. Ninety-six paired (BAL and BW) samples from 85 patients were included. The average age was 53 years, 61 % of the patients were male, and 74.1 % had an underlying diagnosis of AML/MDS (ALL 7.1 %, other hematologic malignancy 18.8 %). 57 (67.1 %) patients were neutropenic, and 56 (65.9 %) patients were receiving mold-active drugs at least 48 h prior to bronchoscopy. The overall agreement between GM detection from BW and BAL was 63.5 % (K = 0.152; 95 % CI 0.008–0.311) and 73 % (K = 0.149; 95 % CI 0.048–0.348) at cut off ≥0.5 and ≥1.0, respectively. Among 43 positive samples, using a GM cut-off of 0.5, 39 (90.5 %) were positive in BW samples whereas 12 (29.3 %) were positive in BAL samples. The median level of GM in BW (0.28) samples was significantly higher than in BAL (0.20) samples among 53 samples with negative results (P = 0.001). There was no statistically significant difference in the median GM values between the BW and BAL samples with positive results (P = 0.08). There was no significant difference in GM detection between samples with positive and negative results with regard to antifungal, beta lactam antibacterial treatment or neutropenia (60.5 vs 56.6 %; 53.9 vs 46 %; 65.1 vs 54.7 %, respectively). This retrospective study examining two collection techniques suggests that BW may have higher diagnostic yield compared to bronchoalveolar lavage for GM detection.Keywords
This publication has 16 references indexed in Scilit:
- The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosisRespiratory Medicine, 2013
- Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosisJournal of Infection, 2010
- Accuracy of BAL Galactomannan in Diagnosing Invasive AspergillosisChest, 2010
- Therapeutic Outcome and Prognostic Factors of Invasive Aspergillosis in an Infectious Disease Department: A Review of 34 CasesInfection, 2008
- Factors Associated with Overall and Attributable Mortality in Invasive AspergillosisClinical Infectious Diseases, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Laboratory diagnosis of invasive aspergillosisThe Lancet Infectious Diseases, 2005
- AspergillusGalactomannan Enzyme Immunoassay and Quantitative PCR for Diagnosis of Invasive Aspergillosis with Bronchoalveolar Lavage FluidJournal of Clinical Microbiology, 2004
- Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patientsEuropean Respiratory Journal, 2001
- Therapeutic Outcome in Invasive AspergillosisClinical Infectious Diseases, 1996